The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...
Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...
Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...
A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or ...
Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.
Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.
Zacks.com on MSN
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma
Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...
The management of treatment side effects can expand caregiver duties significantly, and can involve working more closely with the healthcare team. The symptoms related to multiple myeloma, such as ...
Home > Pressemitteilung: Multiple myeloma: Established cancer ...
The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...
Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain patients with the blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results